127 related articles for article (PubMed ID: 25279574)
1. Myostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia?
Grossmann M
J Clin Endocrinol Metab; 2014 Oct; 99(10):3625-8. PubMed ID: 25279574
[No Abstract] [Full Text] [Related]
2. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
Padhi D; Higano CS; Shore ND; Sieber P; Rasmussen E; Smith MR
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1967-75. PubMed ID: 24971661
[TBL] [Abstract][Full Text] [Related]
3. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
4. Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation.
de Rooy C; Grossmann M; Zajac JD; Cheung AS
Endocr Relat Cancer; 2016 Jan; 23(1):R15-26. PubMed ID: 26432470
[TBL] [Abstract][Full Text] [Related]
5. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
6. Effects of strength training on muscle cellular outcomes in prostate cancer patients on androgen deprivation therapy.
Nilsen TS; Thorsen L; Fosså SD; Wiig M; Kirkegaard C; Skovlund E; Benestad HB; Raastad T
Scand J Med Sci Sports; 2016 Sep; 26(9):1026-35. PubMed ID: 26282343
[TBL] [Abstract][Full Text] [Related]
7. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer.
Chang D; Joseph DJ; Ebert MA; Galvão DA; Taaffe DR; Denham JW; Newton RU; Spry NA
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):223-8. PubMed ID: 24118850
[TBL] [Abstract][Full Text] [Related]
8. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.
O'Connell KE; Guo W; Serra C; Beck M; Wachtman L; Hoggatt A; Xia D; Pearson C; Knight H; O'Connell M; Miller AD; Westmoreland SV; Bhasin S
FASEB J; 2015 Apr; 29(4):1165-75. PubMed ID: 25466897
[TBL] [Abstract][Full Text] [Related]
9. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
[TBL] [Abstract][Full Text] [Related]
10. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.
Koncarevic A; Cornwall-Brady M; Pullen A; Davies M; Sako D; Liu J; Kumar R; Tomkinson K; Baker T; Umiker B; Monnell T; Grinberg AV; Liharska K; Underwood KW; Ucran JA; Howard E; Barberio J; Spaits M; Pearsall S; Seehra J; Lachey J
Endocrinology; 2010 Sep; 151(9):4289-300. PubMed ID: 20573726
[TBL] [Abstract][Full Text] [Related]
11. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice.
Camporez JP; Petersen MC; Abudukadier A; Moreira GV; Jurczak MJ; Friedman G; Haqq CM; Petersen KF; Shulman GI
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2212-7. PubMed ID: 26858428
[TBL] [Abstract][Full Text] [Related]
12. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
13. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
Cheung AS; Zajac JD; Grossmann M
Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
[TBL] [Abstract][Full Text] [Related]
14. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function.
Murphy KT; Koopman R; Naim T; Léger B; Trieu J; Ibebunjo C; Lynch GS
FASEB J; 2010 Nov; 24(11):4433-42. PubMed ID: 20624929
[TBL] [Abstract][Full Text] [Related]
15. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
Galvão DA; Taaffe DR; Spry N; Newton RU
Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
[TBL] [Abstract][Full Text] [Related]
16. Myostatin and sarcopenia: opportunities and challenges - a mini-review.
White TA; LeBrasseur NK
Gerontology; 2014; 60(4):289-93. PubMed ID: 24457615
[TBL] [Abstract][Full Text] [Related]
17. Managing the side effects of androgen-deprivation therapy.
J Support Oncol; 2007 Feb; 5(2):87-8. PubMed ID: 17348368
[No Abstract] [Full Text] [Related]
18. Androgen deprivation therapy and acute kidney injury.
Smith MR
JAMA; 2013 Dec; 310(21):2313. PubMed ID: 24302098
[No Abstract] [Full Text] [Related]
19. Cardiovascular toxicity of androgen deprivation therapy: a new door opens.
Alibhai SM
J Clin Oncol; 2011 Sep; 29(26):3500-2. PubMed ID: 21844507
[No Abstract] [Full Text] [Related]
20. Androgen deprivation therapy and acute kidney injury--reply.
Azoulay L; Benayoun S; Suissa S
JAMA; 2013 Dec; 310(21):2313-4. PubMed ID: 24302099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
